Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07455136

A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and second, for monitoring the development of secondary events in adult participants diagnosed with TBI (CLIN12.2).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Of California Davis, Neurological Surgery, Sacramento, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presenting to the Emergency Department with a biomechanically plausible mechanism of non-penetrating traumatic brain injury (TBI; direct impact: blow to the head, head against object, object against head; acceleration/deceleration)
  • Acute brain CT completed for standard of care

Further Inclusion Criteria (specific for CLIN12.2):

  • Admitted to the hospital with radiographic evidence of acute TBI
  • Admitted to the intensive care unit at risk for decline related to TBI

Exclusion criteria

  • Prior neurosurgical intervention within the last 6 months
  • Major debilitating neurological disease (such as, but not limited to: stroke, CVA, mild cognitive impairment, Alzheimer's disease, Amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, Frontotemporal dementia, tumor, epilepsy, unmanaged seizure disorder), impairing baseline awareness, cognition, or validity of outcomes assessments
  • Major debilitating baseline mental health disorders (such as but not limited to schizophrenia or bipolar disorder) that would interfere with follow-up and the validity of outcome assessments
  • Significant pre-existing conditions that would interfere with follow-up and outcome assessment (such as, but not limited to: chronic kidney disease, chronic cardiovascular comorbidities, alcohol or substance use disorder)
  • History of melanoma
  • Primary diagnosis of ischemic or hemorrhagic stroke
  • Any spinal Cord Injury (American Spinal Injury Association [ASIA] score of A-D)
  • Received chemotherapy or radiation currently or within the last year
  • Patients on psychiatric hold (e.g., 5150, 5250)
  • Current incarceration or in custody
  • Known inability to undergo an MRI
  • Currently receiving any interventional treatments as a part of an investigational study/trial (drug, device, behavioral, treatment) at the time of enrollment and/or during the course of this study
  • Low likelihood of follow-up (e.g. participant or family indicating low interest, residence in another state or country, homelessness or lack of reliable contacts)
  • Any condition that, in the opinion of the investigator, could interfere in the proper execution of the study procedures and/or in their future permanence in the study

Treatment and study plan

blood sample collection

Procedure

Blood samples from each enrolled participant in CLIN12.1 and/or CLIN12.2 will be collected.

Primary outcomes

  1. Percentage of Participants According to Traumatic Brain Injury (TBI) Diagnosis (Positive or Negative), Assessed by an Adjudication Panel Based on Structural Imaging (CT and MRI) and Clinical Summaries

    Time frame: Up to 2 weeks post-injury

  2. Glasgow Outcome Scale-Extended (GOSE)-TBI Scores at Specified Timepoints

    Time frame: Days 14, 28, and 90

  3. Percentage of Participants According to Neuroworsening Result (Positive or Negative), Assessed by an Adjudication Panel Based on Clinical and Radiological Findings

    Time frame: Up to 2 weeks post-injury

  4. Percentage of Hospitalized Participants with Secondary Events, Based on CT Scan Findings per the Standard of Care

    Time frame: Up to 2 weeks post-injury

  5. CLIN12.1: Sensitivity of First Panel of Biomarkers Compared with TBI Diagnosis

    Time frame: From Day 1 to 2 weeks post-injury

  6. CLIN12.1: Specificity of First Panel of Biomarkers Compared with TBI Diagnosis

    Time frame: From Day 1 to 2 weeks post-injury

  7. CLIN12.1: Sensitivity of First Panel of Biomarkers Compared with Neuroworsening Results

    Time frame: From Day 1 to 2 weeks post-injury

  8. CLIN12.1: Specificity of First Panel of Biomarkers Compared with Neuroworsening Results

    Time frame: From Day 1 to 2 weeks post-injury

  9. CLIN12.1: Sensitivity of First Panel of Biomarkers Compared with GOSE-TBI Scores

    Time frame: Days 14, 28, and 90

  10. CLIN12.1: Specificity of First Panel of Biomarkers Compared with GOSE-TBI Scores

    Time frame: Days 14, 28, and 90

  11. CLIN12.2: Sensitivity of a Biomarker Compared with the Development of Secondary Events in Hospitalized Participants with TBI

    Time frame: Up to 2 weeks post-injury

  12. CLIN12.2: Specificity of a Biomarker Compared with the Development of Secondary Events in Hospitalized Participants with TBI

    Time frame: Up to 2 weeks post-injury

Secondary outcomes

  1. CLIN12.1: Sensitivity of Second Panel of Biomarkers Compared with TBI Diagnosis

    Time frame: From Day 1 to 2 weeks post-injury

  2. CLIN12.1: Specificity of Second Panel of Biomarkers Compared with TBI Diagnosis

    Time frame: From Day 1 to 2 weeks post-injury

  3. CLIN12.1: Sensitivity of Second Panel of Biomarkers Compared with Neuroworsening Results

    Time frame: From Day 1 to 2 weeks post-injury

  4. CLIN12.1: Specificity of Second Panel of Biomarkers Compared with Neuroworsening Results

    Time frame: From Day 1 to 2 weeks post-injury

  5. CLIN12.1: Sensitivity of Second Panel of Biomarkers Compared with GOSE-TBI Scores

    Time frame: Days 14, 28, and 90

  6. CLIN12.1: Specificity of Second Panel of Biomarkers Compared with GOSE-TBI Scores

    Time frame: Days 14, 28, and 90

  7. CLIN12.2: Sensitivity of a Second Biomarker Compared with the Development of Secondary Events in Hospitalized Participants with TBI

    Time frame: Up to 2 weeks post-injury

  8. CLIN12.2: Specificity of a Second Biomarker Compared with the Development of Secondary Events in Hospitalized Participants with TBI

    Time frame: Up to 2 weeks post-injury

Study contacts

Contact information is provided by the study sponsor or research team.

Marian Martinez

CONTACT

[email protected]

+1-815-394-9084

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Collaborators

  • Roche Diagnostics GmbH

Registry information

Official study title

A Multicenter Prospective Study to Develop a Blood-based Biomarker Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adult Subjects (CLIN12.1) and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury (CLIN12.2)

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 6, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.